Wang Yanzhong, Wang Saifeng, Zhang Xiaojun, Li Yang, Zhao Shiyu, Meng Songdong
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Sheng Wu Gong Cheng Xue Bao. 2011 May;27(5):790-8.
While currently therapeutic vaccines for chronic hepatitis B virus (HBV) infection are actively being developed to complement standard antiviral treatments, their immune activity, especially T cell activity, remains to be further improved. Here, we investigated the role of heat shock proteins HSP70 and gp96 on cellular and humoral immunity, using the main structure antigens of hepatitis core (HBcAg) and surface (HBsAg) as the DNA vaccine. By ELISPOT (enzyme linked immunospot assay), IFN-gamma intracellular staining, [3H]-thymidine incorporation and ELISA (enzyme linked immunosorbent assay) analyses, we showed that immunization with HBsAg/HBcAg DNA formulation along with HSP70 or gp96 induced significant increase of T-cell (about 1-6-fold) and antibody (about 20%-60%) immunity against HBsAg and HBcAg. These results may provide bases for designing HSP70- and gp96-based vaccines aimed at eliciting T-cell responses for therapeutic applications.
虽然目前正在积极研发用于慢性乙型肝炎病毒（HBV）感染的治疗性疫苗，以补充标准抗病毒治疗，但它们的免疫活性，尤其是T细胞活性，仍有待进一步提高。在此，我们以乙肝核心抗原（HBcAg）和表面抗原（HBsAg）的主要结构抗原作为DNA疫苗，研究了热休克蛋白HSP70和gp96在细胞免疫和体液免疫中的作用。通过酶联免疫斑点分析（ELISPOT）、γ干扰素细胞内染色、[3H]胸腺嘧啶核苷掺入法和酶联免疫吸附测定（ELISA）分析，我们发现用HBsAg/HBcAg DNA制剂联合HSP70或gp96免疫可显著增强针对HBsAg和HBcAg的T细胞免疫（约1至6倍）和抗体免疫（约20%至60%）。这些结果可为设计基于HSP70和gp96的疫苗提供依据，旨在引发T细胞反应以用于治疗应用。
